title: Cationic liposomes as vaccine adjuvants.
abstract: The application of cationic liposomes as vaccine delivery systems and adjuvants has been investigated extensively over the last few decades. However, cationic liposomes are, in general, not sufficiently immunostimulatory, which is why the combination of liposomes with immunostimulating ligands has arisen as a strategy in the development of novel adjuvant systems. Within the last 5 years, two novel adjuvant systems based on cationic liposomes incorporating Toll-like receptor or non-Toll-like receptor immunostimulating ligands have progressed from preclinical testing in smaller animal species to clinical testing in humans. The immune responses that these clinical candidates induce are primarily of the Th1 type for which there is a profound unmet need. Furthermore, a number of new cationic liposome-forming surfactants with notable immunostimulatory properties have been discovered. In this article we review the recent progress on the application of cationic liposomes as vaccine delivery systems/adjuvants.
authors.affiliation: Statens Serum Institut, Department of Infectious Disease Immunology, Copenhagen, Denmark. den@ssi.dk
authors.forename: Dennis
authors.initials: D
authors.lastname: Christensen
authors.forename: Karen Smith
authors.initials: KS
authors.lastname: Korsholm
authors.forename: Peter
authors.initials: P
authors.lastname: Andersen
authors.forename: Else Marie
authors.initials: EM
authors.lastname: Agger
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D006801:Humans; D008081:Liposomes / Q000008:administration & dosage / Q000494:pharmacology*; D014612:Vaccines / Q000008:administration & dosage / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D008081:Liposomes; D014612:Vaccines